DRUG RATIONALIZATION

CONTEXT

Genetic tests have become routinely used as a support in the patient diagnostic pathway. Nevertheless, the association between genetic knowledge and the most appropriate medicine for a given patient remains to be strengthened.

WHY ?

When multiple drugs are available to clinicians, we use biological models expressing genetic variations found in patients to evaluate drug response in a patient-specific environment. Drugs are classified according to their relevance in normalizing defects associated with the variation.

MODELS

Patient-specific genetic variations are expressed in the most relevant biological models:

  • Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CM)

  • Heterologous expression systems (HEK, CHO cells...)

  • Zebrafish

  • Drosophila

  • Nematod (C. Elegans)

TECHNOLOGIES

Biological models are used in combination with the most accurate approaches, including:

  • Electrophysiology (manual and automated path-clamp)

  • Fluorescence microscopy (conventional and confocal)

  • Calcium dynamics recording

  • In-vivo heart function evaluation (Zebrafish)

ADDRESSES

Headquarters

Pépinière Laënnec

BIOPARC

60A Avenue Rockefeller

69008 LYON

FRANCE

Laboratories

Bâtiment IURC Institut Universitaire de Recherche Clinique
641 Avenue du Doyen Gaston Giraud

34090 MONTPELLIER

FRANCE

DIAG'NCELL

SIREN : 849 573 274 R.C.S. Lyon